Lifestance Health Group (LFST) AI Stock Analysis

• Market Cap: $2.71B
• Dividend Yield: N/A
• Average Volume (3M): 2.32M
• Price to Earnings (P/E): 281.2
• Beta (1Y): 0.61
• Revenue Growth: 13.39%
• EPS Growth: 90.55%
• Country: US
• Employees: 7,535
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.01
• Shares Outstanding: 389,783,200
• 10 Day Avg. Volume: 3,735,704
• 30 Day Avg. Volume: 2,318,373
• PEG Ratio: -2.34
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 1.91
• P/FCF Ratio: 24.70
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 1.86
• Enterprise Value/Gross Profit: 6.10
• Enterprise Value/Ebitda: 33.60
• 1Y Price Target: $10.14
• Price Target Upside: 45.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 0.07
• Revenue Forecast (FY): $1.64B

• Rating: 66 Neutral
• Price Target: $8.00 ▲(15.11% Upside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

LFST scores as moderate: improving fundamentals and upbeat 2026 guidance (growth, margin expansion, and positive free cash flow) are the main positives, supported by a constructive technical uptrend. The biggest offset is valuation risk from an extremely high P/E, with still-thin profitability and execution items (notably EHR transition and clinician competition) limiting the score.

Positive Factors

Clinician network & visit scale

A materially larger clinician base and nearly 9M visits provide durable capacity to scale revenue through higher utilization and geographic reach. Bigger clinician scale reduces per-visit overhead, supports payer contracting leverage, and forms a stable revenue floor as the outpatient behavioral-health market grows.

Stronger free cash flow and manageable leverage

Consistent positive free cash flow and a modest net debt position improve financial flexibility for investment, tuck-in M&A, and the $100M buyback. Durable cash generation lowers refinancing risk, funds EHR and center openings, and supports the shift from growth-funded losses to self-funded expansion.

Tech/AI-driven productivity gains

Sustained adoption of digital and AI tools can permanently raise clinician productivity and booking efficiency, enabling more visits per clinician with lower admin time. These structural efficiency gains support margin expansion across centers and reduce reliance on purely labor-driven growth.

Negative Factors

Decelerating revenue growth and thin margins

A sharp growth slowdown and only modest net/EBIT margins leave limited cushion for execution hiccups. If visit growth or revenue-per-visit improvements falter, thin margins could revert the company to losses, making durable profitability dependent on continued productivity and pricing gains.

EHR transition execution risk

Enterprise EHR rollouts commonly disrupt scheduling, billing and clinician workflows for quarters. Even if largely capitalized, the $20–30M cash spend plus productivity drag can depress near-term margins and slow revenue capture from new centers, posing multi-quarter operational risk.

Labor competition and sizable SBC run-rate

Persistent local labor competition forces ongoing incentives and hiring costs; coupled with a large stock-based compensation run-rate, this structurally elevates operating expenses. High recurring people costs constrain margin upside and reduce free cash flow available for reinvestment or returns unless productivity gains outpace labor inflation.

Lifestance Health Group Business Overview & Revenue Model

Company Description

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. It serves children, adolescents, adults, and geriatrics. LifeStance Health Group, Inc. was founded in 2017 and is based in Scottsdale, Arizona.

How the Company Makes Money

Lifestance Health Group generates revenue primarily through the provision of mental health services billed to patients and their insurance providers. The company's revenue model is based on fee-for-service arrangements, where patients pay for individual therapy sessions, psychiatric evaluations, and ongoing treatment plans. Key revenue streams include reimbursements from private health insurance companies, Medicare, and Medicaid for covered services, as well as out-of-pocket payments from patients. Additionally, LFST may engage in partnerships with healthcare organizations and insurers to expand its patient base and enhance service delivery, which can also contribute to its earnings.

Lifestance Health Group Financial Statement Overview

Summary

Results show a multi-year turnaround: revenue scaled materially through 2025, profitability flipped positive in 2025, leverage improved (debt-to-equity ~0.13), and operating/free cash flow strengthened. Offsetting this, growth has decelerated sharply and margins remain thin, so the durability of the improvement is still being proven.

Income Statement

Revenue has grown consistently from $377M (2020) to $1.424B (2025), but growth has decelerated materially (from ~77% in 2020 to ~4% in 2025). Profitability has improved sharply: the company moved from large losses in 2021–2024 to positive results in 2025 (net margin ~0.7% and EBIT margin ~1.7%), suggesting an inflection point. The key weakness is that margins remain thin and recent history includes multiple years of meaningful losses, so the durability of the turnaround is not yet proven.

Balance Sheet

Leverage looks manageable and improving: debt-to-equity declined from ~0.34–0.36 (2023–2024) to ~0.13 in 2025, supported by a sizable equity base ($1.52B) versus debt ($194M). Total assets are relatively stable around ~$2.1–$2.2B, indicating balance sheet scale without heavy recent expansion. The main weakness is that returns on equity have been weak/negative for several years and only recently turned slightly positive (~0.6% in 2025), which implies limited profitability relative to capital.

Cash Flow

Cash generation improved meaningfully: operating cash flow rose from negative in 2023 to $107M (2024) and $146M (2025), and free cash flow turned solidly positive ($146M in 2025) with strong growth (~22% in 2025). Cash flow has generally tracked earnings better recently, but a caution flag is that operating cash flow still covers only about 58% of debt in 2025 (improved vs. prior years, but not robust), and cash flow was volatile earlier in the period with negative free cash flow in multiple years.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.42B	1.25B	1.06B	859.54M	667.51M
Gross Profit	406.35M	402.40M	302.10M	237.02M	201.51M
EBITDA	78.78M	39.87M	-104.93M	-143.60M	-240.06M
Net Income	9.66M	-57.44M	-186.26M	-215.56M	-307.20M
Balance Sheet
Total Assets	2.20B	2.12B	2.11B	2.17B	1.93B
Cash, Cash Equivalents and Short-Term Investments	248.64M	154.57M	78.82M	108.62M	148.03M
Total Debt	194.10M	485.19M	511.04M	478.83M	158.74M
Total Liabilities	682.92M	672.01M	681.04M	655.15M	382.08M
Stockholders Equity	1.52B	1.45B	1.43B	1.52B	1.55B
Cash Flow
Free Cash Flow	110.03M	85.69M	-57.40M	-26.47M	-85.07M
Operating Cash Flow	146.15M	107.26M	-16.88M	52.79M	9.42M
Investing Cash Flow	-36.13M	-21.57M	-60.34M	-139.46M	-194.08M
Financing Cash Flow	-15.96M	-9.95M	47.43M	47.26M	313.86M

Lifestance Health Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.95
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFST, the sentiment is Negative. The current price of 6.95 is below the 20-day moving average (MA) of 7.05, below the 50-day MA of 7.13, and above the 200-day MA of 5.84, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 32.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFST.

Lifestance Health Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	78 Outperform	$2.61B	17.67	9.94%	1.80%	23.74%	-18.99%
LFST	66 Neutral	$2.71B	281.23	0.65%	―	13.39%	90.55%
SEM	62 Neutral	$2.02B	12.54	5.57%	1.69%	-22.96%	-59.35%
BKD	58 Neutral	$3.50B	-9.62	-214.33%	―	3.93%	-42.22%
AVAH	52 Neutral	$1.52B	32.50	―	―	15.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACHC	50 Neutral	$2.27B	-1.17	-43.91%	―	4.58%	-61.50%

Lifestance Health Group Corporate Events

LifeStance Health Guides 2026 Growth, Announces Buyback Program

On February 25, 2026, LifeStance Health Group reported that fourth-quarter 2025 revenue rose 17% year over year to $382.2 million and full-year revenue climbed 14% to $1.42 billion, driven by an expanded clinician base, higher visit volumes and improved productivity. The company swung to positive net income of $11.7 million in the quarter and $9.7 million for 2025, expanded Adjusted EBITDA by 49% in the quarter to $48.8 million, generated $146.2 million in operating cash flow for the year and ended 2025 with a solid cash position and moderate net debt.

Management issued 2026 guidance calling for further growth to $1.615 billion–$1.655 billion in revenue and higher Center Margin and Adjusted EBITDA, signaling confidence in continued operating leverage. The board also authorized a $100 million share repurchase program, underscoring LifeStance’s improved profitability and cash generation and suggesting a stronger capital return profile that could enhance shareholder value while the company continues to invest in long-term expansion.

The most recent analyst rating on (LFST) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lifestance Health Group stock, see the LFST Stock Forecast page.